EUVIMEDEUVIMED entdecken
Crossref

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Killian Donovan, William Guy Herrington, Paré, Guillaume, Marie Pigeyre, Richard Haynes, Sardell, Rebecca, Butterworth, Adam S, Lasse Folkersen, Stefan Gustafsson und 8 weitere

Apollo (University of Cambridge) · 01.01.2023

DOI: 10.17863/cam.94553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apollo (University of Cambridge), erschienen am 01.01.2023. Verfasst von Killian Donovan und 19 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Fibroblast growth factor-23 (FGF-23) is associated with a range of cardiovascular and noncardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding. METHODS: SCALLOP Consortium data of 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease (n=26,266 events), nonatherosclerotic cardiovascular disease (n=12,652), and noncardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n=181,249 cases), MEGASTROKE (stroke, n=34,217), and HERMES (heart failure, n=47,309). RESULTS: We identified 34 independent variants for circulating FGF-23, which formed a validated genetic score. There were no associations between genetically predicted FGF-23 and any of the cardiovascular or noncardiovascular outcomes. In UK Biobank, the odds ratio (OR) for any atherosclerotic cardiovascular disease per 1-SD higher genetically predicted logFGF-23 was 1.03 (95% confidence interval [95% CI], 0.98 to 1.08), and for any nonatherosclerotic cardiovascular disease, it was 1.01 (95% CI, 0.94 to 1.09). The ORs in the case-control consortia were 1.00 (95% CI, 0.97 to 1.03) for coronary artery disease, 1.01 (95% CI, 0.95 to 1.07) for stroke, and 1.00 (95% CI, 0.95 to 1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalities. CONCLUSIONS: Genetically predicted FGF-23 levels are not associated with atherosclerotic and nonatherosclerotic cardiovascular diseases, suggesting no important causal link. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_01_10_CJN05080422.mp3.

Schlagwörter

fibroblast growth factor 23cardiovascular riskatherosclerotic cardiovascular diseasecoronary artery diseasestrokeheart failurecarotid intima-media thicknessleft ventricular massgenetic scoreresidual confounding

Zitieren

APA

Donovan, K., Herrington, W. G., Paré, Guillaume, Pigeyre, M., Haynes, R., Sardell, Rebecca, Butterworth, S, A., Folkersen, L., Gustafsson, S., Wang, Qin, Baigent, C., Mälarstig, A., Holmes, M. V., Staplin, Natalie, & Consortium, O. B. O. T. S. (2023). Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study. Apollo (University of Cambridge). https://doi.org/10.17863/cam.94553

Vancouver

Donovan K, Herrington WG, Paré, Guillaume, Pigeyre M, Haynes R, et al. Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study. Apollo (University of Cambridge). 2023. doi:10.17863/cam.94553

BibTeX
@article{Donovan2023,
  author = {Donovan, Killian and Herrington, William Guy and Paré and Guillaume and Pigeyre, Marie and Haynes, Richard and Sardell and Rebecca and Butterworth and S, Adam and Folkersen, Lasse and Gustafsson, Stefan and Wang and Qin and Baigent, Colin and Mälarstig, Anders and Holmes, Michael Vaclav and Staplin and Natalie and Consortium, on behalf of the SCALLOP},
  title = {Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study},
  journal = {Apollo (University of Cambridge)},
  year = {2023},
  doi = {10.17863/cam.94553}
}
Kostenlos starten →